Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands: the OCEAN study.

Several clinical studies have shown superiority of azacitidine compared to conventional care regimens in frail patients with MDS and AML [[1]]. In 57 (65%) of 87 patients without HI, and in 51 (81%) of the 63 patients that stopped treatment within 6 cycles, no BME was performed. In 13 out of 22 patients, the dose reduction was done before HI was reached, in 3 of them a BME was done before dose reduction (1 patient had CRi, and 2 patients had SD). Thirteen (6%) patients stopped treatment after the 1st cycle of azacitidine and 63 (37%) patients stopped within 6 cycles. [Extracted from the article]